G. Xie

Publications24
h-index13
Citations479
Highly Influential Citations8
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • B. Rigas
  • 235 Publications • 10,967 Citations
  • Liqun Huang
  • 75 Publications • 1,330 Citations
  • N. Ouyang
  • 89 Publications • 3,235 Citations
  • G. Mackenzie
  • 88 Publications • 2,213 Citations
  • Publications
  • Influence
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
TLDR
The findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.
View on PubMed
The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
TLDR
Three novel modified NSAIDs are evaluated for the anti‐inflammatory efficacy and safety in rheumatoid arthritis: phospho‐aspirin,ospho‐ibuprofen and phospho-sulindac.
View on Wiley
Regioselective oxidation of phospho‐NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety
TLDR
Phospho‐ibuprofen and phospho‐sulindac metabolism by major human cytochrome P450s (CYPs) and flavin monooxygenases (FMOs) is investigated.
View on Wiley
Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models
  • G. Xie, Yu Sun, B. Rigas
  • Biology, Chemistry
    Journal of Pharmacology and Experimental…
  • 1 June 2011
TLDR
The results provide a pharmacological basis to explain, at least in part, the anticancer efficacy and safety of this promising compound and indicate that PI merits further evaluation as an anticancer agent.
View on Publisher
Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice
TLDR
P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac.
View on Publisher
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
TLDR
OXT-922 possesses promising anticancer properties and deserves further evaluation, and enhanced spermidine/spermine N(1)-acetyltransferase activity, reduced the cellular polyamine content and synergized with difluoromethylornithine to inhibit cancer cell proliferation and induce apoptosis.
View on PubMed
Phospho-NSAIDs Have Enhanced Efficacy in Mice Lacking Plasma Carboxylesterase: Implications for their Clinical Pharmacology
TLDR
Investigation of the metabolism, pharmacokinetics and efficacy of phospho-NSAIDs in Ces1c-knockout mice indicates that intact phospho/sulindac are the pharmacologically active entities andospho- NSAIDs are expected to be more efficacious in humans than in rodents due to their differential expression of carboxylesterases.
View on Springer
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
BACKGROUND & AIMS Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective cancer chemopreventive agents. However, chronic administration of NSAIDs is associated with significant side effects,…
View on PubMed
Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity
TLDR
Results show that carboxylesterase mediates that metabolic inactivation of phospho-NSAIDs, and the inhibition of carboxyleterases improves the efficacy of phosphate- NSAIDs in vitro and in vivo.
View on Publisher
The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine
TLDR
Phospho‐sulindac prevents colon cancer in mice, especially when combined with difluoromethylornithine (DFMO) and here, its metabolism and pharmacokinetics are explored.
View on Wiley
...
...